Selecta Biosciences

Selecta Biosciences company information, Employees & Contact Information

In November 2023, Selecta Biosciences Inc. (NASDAQ: SELB) merged with Cartesian Therapeutics to create a publicly traded company pioneering RNA cell therapy to treat autoimmune disease. The combined company will focus on advancing Cartesian’s wholly owned pipeline, including Descartes-08, Cartesian’s clinical-stage lead product candidate being evaluated in patients with myasthenia gravis and other autoimmune diseases. For more information about the company and updates, please visit https://www.cartesiantherapeutics.com/ or follow us on LinkedIn @Cartesian-Therapeutics.

Company Details

Employees
12
Address
65 Grove Street, Watertown,ma 02472,united States
Phone
(617) 923-1400
Email
in****@****bio.com
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
HQ
Watertown, MA
Looking for a particular Selecta Biosciences employee's phone or email?

Selecta Biosciences Questions

News

Selecta Announces Transition of Manufacturing and Clinical Operations of ImmTOR for SEL-212 to Commercialization Partner Sobi - Yahoo Finance

Selecta Announces Transition of Manufacturing and Clinical Operations of ImmTOR for SEL-212 to Commercialization Partner Sobi Yahoo Finance

Selecta Biosciences Appoints Nishan de Silva, M.D. to Board of Directors - citybiz

Selecta Biosciences Appoints Nishan de Silva, M.D. to Board of Directors citybiz

Selecta Biosciences and Astellas Announce Exclusive Licensing and Development Agreement for Xork IgG Protease - PR Newswire

Selecta Biosciences and Astellas Announce Exclusive Licensing and Development Agreement for Xork IgG Protease PR Newswire

Enhancement of liver-directed transgene expression at initial and repeat doses of AAV vectors admixed with ImmTOR nanoparticles - Science | AAAS

Enhancement of liver-directed transgene expression at initial and repeat doses of AAV vectors admixed with ImmTOR nanoparticles Science | AAAS

Addressing Unwanted Immunogenicity in Gene Therapies - BioProcess International

Addressing Unwanted Immunogenicity in Gene Therapies BioProcess International

Sobi and Selecta Bio Gout Drug Hits Phase 3 Goals, Paving Way for FDA Submission - MedCity News

Sobi and Selecta Bio Gout Drug Hits Phase 3 Goals, Paving Way for FDA Submission MedCity News

Top Selecta Biosciences Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant